Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2017 | Should we be focusing on treating MM?

Gareth Morgan, MD, FRCP, FRCPath, PhD, from the Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, talks to us about current cutting-edge therapies in the potential treatment of melanoma. He describes that the use of immune checkpoint inhibitors with CAR T-cells appears particularly promising, as their combination has been shown to enhance their activity in treating melanoma. A need to shift focus from multiple myeloma to other diseases is also needed, as stated by Prof. Morgan, to understand the structure of the disease microenvironment as a way of predicting patients’ responses to different immunotherapies. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.